Skip to main content

Clinical trials

  • NKARTA NKX019-102

    This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune…

    Investigator
    Michael R Bubb
    Ages
    18 Years - 75 Years
    Sexes
    All